NEW YORK, December 30, 2025, 18:51 ET — After-hours
- Johnson & Johnson shares were down about 0.3% in after-hours trading, around $206.91.
- J&J said it completed its $3.05 billion cash acquisition of oncology-focused biotech Halda Therapeutics.
- The company flagged an expected hit to adjusted EPS and set a Jan. 21 earnings call as the next key checkpoint.
Johnson & Johnson (JNJ) shares edged lower in after-hours trading on Tuesday after the healthcare conglomerate said it had completed its acquisition of Halda Therapeutics. The stock was down 0.3% at $206.91.
The completion matters because investors are resetting portfolios into year-end with interest rates back in focus and dealmaking under a brighter spotlight. For J&J, the question is whether a new oncology platform can expand its pipeline without pressuring near-term profit metrics.
The timing also pushes the spotlight onto management’s next set of targets. With the company set to talk through 2026 guidance in January, investors are looking for a clearer bridge from today’s pipeline spending to future earnings.
J&J announced the Halda agreement in November, saying the $3.05 billion cash deal would close after standard conditions, including antitrust clearance.
On Monday, J&J said it had closed the purchase for $3.05 billion in cash, adding Halda’s Regulated Induced Proximity TArgeting Chimera (RIPTAC) platform and lead prostate cancer program HLD-0915. “This strategic milestone underscores our commitment to redefining cancer treatment with breakthrough science and transformative medicines,” Jennifer Taubert, executive vice president and worldwide chair of Innovative Medicine at J&J, said. J&J said it expects about $0.20 of dilution to adjusted earnings per share — profit per share excluding certain items — split evenly between 2025 and 2026, and will provide commentary on full-year 2026 guidance on its Jan. 21 earnings call. JNJ.com
RIPTAC is a platform chemistry designed to steer drug action by bringing targets into proximity, a bet on more precise, oral targeted therapies. That is an attractive pitch, but it also means the value hinges on clinical execution, not near-term revenue.
The broader tape offered little help. U.S. stocks ended modestly lower on Tuesday after minutes from the Federal Reserve’s last meeting showed policymakers divided over the path for rates.
Big pharma trading was mixed, with Pfizer narrowly lower and Abbott higher in the session.
For J&J investors, attention now shifts to the size and timing of the integration bill and what, if anything, changes in the company’s medium-term growth profile. Updates on HLD-0915’s clinical development and the broader RIPTAC pipeline are likely to be the next stock-specific catalysts.
Technically, JNJ is still below its Dec. 15 record high of $215.19, leaving traders watching whether it can hold near Tuesday’s lows as 2025 winds down. With a market value around $500 billion, the Halda price tag is manageable, but the bar remains high for proof the platform can move earnings over time.
Until management sets expectations for 2026 on Jan. 21, the stock may trade more like a defensive bellwether than a single-news story. In the near term, thin liquidity and rate expectations are likely to keep the day-to-day move modest.
Related articles: NYSE:JNJ
